Sildenafil in the treatment of pulmonary hypertension

• Main Authors: O. S. Groznova, I. V. Leontyeva, O. V. Todorova
• Format: Article
• Language: Russian
• Published: Ltd. “The National Academy of Pediatric Science and Innovation” 2016-03-01
• Series: Rossijskij Vestnik Perinatologii i Pediatrii
• Subjects: children; pulmonary hypertension; prevalence; classification; clinical picture; treatment; phosphodiesterase 5 inhibitor; sildenafil; cardiorespiratory test.
• Online Access: https://www.ped-perinatology.ru/jour/article/view/286

The paper describes the clinical use of a phosphodiesterase 5 inhibitor (sildenafll) in a patient with primary pulmonary hypertension during a long-term controlled follow-up. The 6-year use of sildenafll as monotherapy for pulmonary hypertension had a significant positive effect as a decrease in the functional class of pulmonary hypertension from 3 to 1, an increase in exercise tolerance, improvements in echocardiographic parameters and biochemical markers (brain natriuretic peptide), and a rise in oxygen uptake during cardiorespiratory testing.